Literature DB >> 9345198

Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis.

E C Rodríguez-Merchán1.   

Abstract

The most common clinical manifestation of hemophilia is intraarticular bleeding (hemarthrosis). Although any joint can be involved, the articulations most frequently affected are the knees, elbows, and ankles. Hemorrhages may occur spontaneously, or as a result of trauma. Because hemophilia is a genetically determined coagulation disorder, the bleeding incidences may start early in a child's life. After several hemarthroses, hemophilic synovitis will develop and, because of the profusion and fragility of vessels within the tissue, will lead to a vicious cycle of bleeding-synovitis-bleeding. If the synovitis is not controlled, cartilage damage will occur. hemophilic arthropathy then will become apparent clinically and radiographically, causing functional impairment of the affected joint. Prophylaxis and early diagnosis of acute hemarthrosis are essential to prevent the development of hemophilic synovitis. Hemarthroses must be treated aggressively if hemophilic synovitis is to be prevented. Continuous prophylaxis from age 2 to 18 years has been claimed to reduce the incidence of chronic hemophilic synovitis and joint damage, which remain the main causes of disability in the life of the patient who has hemophilia.

Entities:  

Mesh:

Year:  1997        PMID: 9345198

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  18 in total

1.  Presentation of severe haemophilia--a role for accident and emergency doctors?

Authors:  H L Minhas; P L Giangrande
Journal:  Emerg Med J       Date:  2001-07       Impact factor: 2.740

2.  Joint haemorrhage partly accelerated immobilization-induced synovial adhesions and capsular shortening in rats.

Authors:  Yoshito Onoda; Yoshihiro Hagiwara; Akira Ando; Takashi Watanabe; Eiichi Chimoto; Hideaki Suda; Yutaka Yabe; Yoshifumi Saijo; Eiji Itoi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-09-08       Impact factor: 4.342

3.  Trauma resulting in hemarthrosis and long medial collateral ligament desmitis of the tarsocrural joint in a horse.

Authors:  Nathalie Tokateloff; James Carmalt; Stephen Manning
Journal:  Can Vet J       Date:  2011-05       Impact factor: 1.008

4.  Blood exposure has a negative effect on engineered cartilage.

Authors:  C Sosio; F Boschetti; L Mangiavini; C Scotti; S Manzotti; M S Buragas; S Biressi; G Fraschini; A Gigante; G M Peretti
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2010-10-28       Impact factor: 4.342

5.  Neoangiogenesis contributes to the development of hemophilic synovitis.

Authors:  Suchitra S Acharya; Rosandra N Kaplan; Dan Macdonald; Oluwa T Fabiyi; Donna DiMichele; David Lyden
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

6.  Total hip replacement in patients with severe bleeding disorders. A 30 years single center experience.

Authors:  B Habermann; C Eberhardt; L Hovy; L Zichner; I Scharrer; A A Kurth
Journal:  Int Orthop       Date:  2006-05-20       Impact factor: 3.075

7.  Effect of blood on the morphological, biochemical and biomechanical properties of engineered cartilage.

Authors:  C Sosio; F Boschetti; C Bevilacqua; L Mangiavini; C Scotti; M S Buragas; S Biressi; G Fraschini; A Gigante; G M Peretti
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2007-05-12       Impact factor: 4.342

Review 8.  Advances and challenges in hemophilic arthropathy.

Authors:  Tine Wyseure; Laurent O Mosnier; Annette von Drygalski
Journal:  Semin Hematol       Date:  2015-10-26       Impact factor: 3.851

Review 9.  Treatment strategies in children with hemophilia.

Authors:  Pia Petrini
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 10.  A cellular viewpoint of anti-FVIII immune response in hemophilia A.

Authors:  Sebastien André; Yann Meslier; Jordan D Dimitrov; Yohann Repessé; Srinivas V Kaveri; Sebastien Lacroix-Desmazes; Suryasarathi Dasgupta
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.